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ABSTRACT 
Melanoma represents one of the most aggressive and lethal forms of skin cancer, with 
annually rising incidences throughout the world. Although chemotherapy modalities remain the 
mainstay of treatment, the therapeutic potential of chemotherapy typically is hampered by 
multidrug resistance (MDR) and nonspecific drug distribution that causes side-effects. To 
surmount such limitations, novel nanoformulations of low band-gap poly ({4,8-bis [(2-ethylhexyl) 
oxy] benzo [1,2-b:4,5-b′] dithiophene-2,6-diyl}{3-fluoro-2-[(2-ethylhexyl) carbonyl] thieno [3,4-
b] thiophenediyl}) (PTB7) and poly [2,1,3-benzothiadiazole- 4,7- diyl [4,4-bis (2-ethylhexyl)- 4H-
cyclopenta [2,1-b:3,4-b’] dithiophene-2,6-diyl]] (PCPDTBT) were fabricated by a reprecipitation 
method. These conjugated polymer nanoparticles were functionalized with the polypeptide 
endothelin-3 (EDN3-CPNPs) to target melanoma. The combination of EDNRB and EDN3 is 
unique to melanoma’s endothelin axis in an otherwise healthy body. Therapeutic effects were 
studied in vitro for photodynamic (PDT) and chemodynamic (CDT) therapy applications. The 
PTB7 derived EDN3-CPNPs showed limited PDT effect and were difficult to handle due to 
challenges with preparation and poor colloidal stability. We, therefore, moved forward with 
PCPDTBT as an alternative polymer. Here, we serendipitously discovered that the PCPDTBT 
derived EDN3-CPNPs efficiently and specifically kill tumor cells that overexpress the endothelin 
B receptor agonized by EDN3. We found that tumor cell killing proceeds through ferroptosis, a 
reactive oxygen species (ROS) mechanism that is not dependent on external activation by, for 
example, light, as is the case in PDT. The EDN3-CPNPs obtained from PCPDTBT are loaded with 
iron (Fe3+) that is a residual catalyst of the polymer synthesis. This iron content catalyzes 
 iv 
ferroptosis in the cells. The ferroptosis mechanism is also not heavily reliant on oxygen availability 
and is, therefore, promising for the treatment of hypoxic tumors. The resulting hydroxyl radicals 
(•OH) can rapidly oxidize bio-macromolecules, cause damage to DNA, and reduce tumor cell 
population. The results reported in this dissertation demonstrate that melanoma targeted EDN3-
CPNPs present a new therapeutic avenue. In the future, this approach can be broadened to other 
tumors by replacing the targeting ligand to address cases where conventional methods are not 
feasible or no longer effective. 
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SUMMARY 
The dissertation presented herein consists of five chapters. Chapter 1 is an introduction to 
the research scope discussed in this dissertation, addressing the background and significance of 
the research. It offers knowledge on various types of proposed melanoma treatments: surgery, 
radiation therapy (RT), photodynamic therapy (PDT), chemotherapy, and their mechanisms of 
treating the diseases, as well as their disadvantages and problems. In particular, it focuses on 
discussions on how these problems have been tackled with the development of novel tumor-
targeted polymer nanoparticles carrying iron for chemodynamic therapy (CDT). Then, I comprise 
the literature review by discussing previous research on my subject. Chapter 2 consists of 
materials, methods, and preliminary discussions for the methods used in this dissertation research. 
Chapter 3 includes results and discussion of the observations made on using polymeric 
nanoparticles of PTB7 for photodynamic therapy (PDT) of melanoma skin cancer. Chapter 4 
contains results and discussion of the observations made on using polymer nanoparticles carrying 
iron for chemodynamic therapy (CDT) on various cancer cell lines. Chapter 5 finishes off with the 
conclusions of this dissertation research.     
 
 1 
CHAPTER ONE: INTRODUCTION 
1.1 Background and Significance 
1.1.1 Melanoma 
Melanoma is the most aggressive form of skin cancer, with annually rising incidences 
throughout the world. It is caused by the uncontrolled division of melanocytes (pigment cells) in 
the basal layer of the epidermis (Figure1) and has limited treatment options.1 Melanoma cells can 
migrate through the bloodstream and lymph system from an original site to another location.1 The 
uncontrollable growth can disable normal functions of the body, and in severe cases, cause death.2  
 
Figure 1: Illustration showing a melanocyte-melanin producing cells (adapted from Google image 
references).  
 
 2 
Three main attributes categorize melanomas: the thickness of the primary tumor, the spread 
to lymph nodes, and metastasis that together determine their stage. Wallace H. Clark Jr. discovered 
the stages at Massachusetts General Hospital and Harvard University in the 1960s. Figure 2 
represents Clark's level demonstrating a staging system that describes the depth of melanoma as it 
grows in the skin. In Clark’s Level I, melanomas have been characterized by having a primary 
tumor that is un-ulcerated with a thickness less than 1mm and has not spread to the lymph nodes 
(the tumor is localized in the epidermis). In Level II, melanomas are characterized by having a 
primary tumor that is between 1 and 4 mm thick, which may be ulcerated but has not yet spread to 
the lymph nodes. A Level III melanoma is characterized by having a primary tumor that has spread 
to nearby lymph nodes (cancer has spread into the papillary-reticular dermal interface through the 
papillary dermis). Finally, in Level IV, melanomas have been characterized by having spread to 
distant lymph nodes and the subcutaneous tissue.  
 
 
 
 
  
 
 3 
 
Figure 2: Clark's levels. 
1.1.2 Environmental Factors and Prevention 
Ultraviolet (UV) radiation exposure is recognized as a significant environmental risk factor 
for melanoma.3, 4 However, ultraviolet light in the A spectrum is a longer wavelength, which 
accounts for approximately 95% of the ultraviolet (UV) radiation reaching the lower atmosphere 
and the Earth's surface. These UVA rays go into the skin further compared to UVB rays and mutate 
DNA via producing reactive oxygen species (ROS) that cause oxidative stress (significant damage 
to cell structures) and cytotoxic environment (Figure 3).5, 6 
 4 
 
Figure 3: Illustration shows a cross section of human skin tissue. 
The epidermis allows only 17.5% of UVA and 7.4% of UVB to penetrate in black skin, 
while skin penetration of white skin reaches 55% of UVA and 24% of UVB.7 Figure 4 represents 
a relationship between the incidence of UV rays, people's skin color, and the risk of skin cancer.8 
 5 
 
Figure 4: A relationship between the incidence of UV rays, people's skin color, and the risk of 
skin cancer (reproduced from reference).8 
 
Figure 4 shows how sunscreen filters work to block and absorb UV rays.8 Sunscreen can 
filter out UV rays by combining two types of ingredients. Inorganic ingredients, such as titanium 
or zinc oxides, scatter or reflect UV rays by forming a physical barrier. Meanwhile, organic 
ingredients, such as oxybenzone or octyl methoxycinnamate, absorb and dissipate UV rays as heat.  
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Figure 5: Sunscreen filters reflect UV radiation–Illustration (adapted from Google image 
references). 
 
1.1.3 Melanoma Statistics 
Based on the statistics of 2017, approximately 87,110 individuals were newly diagnosed 
with cases of melanoma in the United States alone.9, 10 On the other hand, reported cases were 
nearly 76,100 for the year 2014, with an estimated 9,710 expected deaths.11 Expected new 
melanoma cases and deaths in 2020, according to The Centers for Disease Control and Prevention, 
are shown in Figure 6. Thanks to the recent development of early diagnosis and treatment of 
melanoma, the growth in the number of deaths by melanoma has been suppressed.  
 7 
 
Figure 6: Actual and projected cancer incidence rates, United States, 1975 to 2020. 
Source: Reproduced from The Centers for Disease Control and Prevention.          
https://www.cdc.gov/cancer/dcpc/research/articles/cancer_2020_incidence.htm 
1.1.4 The Endothelin Axis’ Role in Melanoma  
Endothelins (EDN) are three structurally similar peptides incorporating 21-amino acids. 
EDN1, EDN2, and EDN3, as shown in Figure 7, can bind to two subtypes of G-protein-coupled 
heptahelical receptors, namely endothelin receptor A and endothelin receptor B (EDNRA and 
EDNRB).12, 13 The EDN axis is accepted to assume a role in different malignancies, including 
melanoma, central nervous system tumors, prostate, ovarian, cervical, and breast carcinomas.14  
Four types of EDN receptors have been distinguished: EDNRA, EDNRB, EDNRC, and 
EDNRAX. In mammalian animals, just EDNRA and EDNRB exist. Both EDNRA and EDNRB 
are proteins consisting of 400 amino acids located on the surface of cells.15 The genes for EDN1, 
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EDN2, EDN3, EDNRA, and EDNRB are located on chromosomes 6, 1, 20, 4, and 13, 
respectively.16 The two most essential receptors share excellent arrangement homology and can be 
recognized by their specificity. EDNRA binds most strongly to EDN1 compared to EDN2, 
whereas it shows the lowest affinity to EDN315 [EDN1>EDN2>>EDN3].17 In contrast, EDNRB  
has an equal affinity for all three endothelin isoforms. EDN1, EDN2, and EDN3 with equal affinity 
[EDN1=EDN2=EDN3].18 Endothelin-B receptors (EDNRB) are overexpressed in melanoma and 
considered as a sign of its development progression as determined from 159 human melanoma 
cases.19 Past investigations have shown expression of EDNRB in eleven different cell lines of 
malignant melanoma, though just a single of these cell lines showed additional characterized by 
expression of EDNRA.20, 21 Reports indicate that EDNRB expression increases in melanoma cells 
as they progress to the metastatic disease state.22, 23 The endothelin 3 peptide (EDN3) was found 
to internalize rapidly into the surface of melanoma cells.24 The receptors recognize their 
corresponding agonist through complementarity-determining region loops, specifically between 
the EDNRB binding pocket and the N-terminal amine of EDN3, which is deeply buried within the 
EDNRB pocket during the interaction.25  
 
 9 
 
Figure 7: Structures of the endothelin peptides. 
1.2 Melanoma Therapies 
There are various types of proposed melanoma treatments: surgery, radiation therapy (RT), 
photodynamic therapy (PDT), chemotherapy, chemodynamic therapy (CDT), and their 
combinations.26 The treatment of melanoma depends on the site of the tumor and the stage of the 
disease. Early-stage that has not grown deeply (not metastasized) to the lymph nodes or the 
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surrounding tissue can be eliminated through chemo-surgical treatment successfully with a 99% 
survival rate.27, 28 Surgery is the physical removal of the cancerous tissue or tumor from a specific 
place in the body. Surgical excision removes the melanoma tissue along with some normal tissue 
around it (called the surgical margin). 29 Surgery is the most invasive method but enables the 
removal of a large volume of the tumor area during the localized early stage. However, advanced 
stages (III-IV), highly aggressive malignant skin cancer (metastatic melanoma) are notoriously 
difficult to eradicate through surgical removal and exhibit survival rates of less than 10% in 5 
years. Radiation therapy (RT), performed utilizing an external radiation source, causes 
dysfunctions DNA in the cancer cells through apoptosis.30, 31 Photodynamic therapy (PDT), on the 
other hand, is a clinically approved procedure for melanoma treatment. It is a relatively new form 
of treatment that uses a unique drug, known as a photosensitizer, along with the particular type 
and a specific wavelength of light which utilizes reactive oxygen species (ROS), produced by 
photosensitizers. ROS can exert their selective cytotoxic effects on malignant cells resulting in cell 
death (phototoxicity).26 Chemotherapy is a drug therapy used to destroy cancer cells. It attacks 
cancer cells with small molecules targeted towards rapid growth or biomarkers that are highly 
expressed in the tumor area to prevent cells from spreading, dividing to make more cells, and 
slowing their growth.32, 33  
Radiation therapy and chemotherapy are indirect treatments and less invasive.26 Due to 
their lesser invasiveness, these therapies are often prescribed before surgery or after the surgery as 
adjuvant therapies.33, 34 
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All these types of therapies target the removal of melanoma cells from the human body. 
However, patients still have low response rates and serious adverse effects. Therefore, establishing 
new methods of treatment of advanced melanoma stages (III-IV) is in high demand. 
1.2.1 Problems with Chemotherapy  
Chemotherapy is used in clinical practice as conventional therapy for metastatic melanoma. 
Even though chemotherapy is less invasive, chemotherapeutic agents damage both malignant and 
healthy cells due to their non-specificity and patients may show drug resistance.35 Therefore, side 
effects due to non-targeted distribution of drugs occur that limit the dosage to be used.26 Drug 
resistance is due to cancer cells’ intrinsic resistance against these drugs, the so-called multidrug 
resistance (MDR).36 Because of their MDR ability, some cancer cells may survive 
chemotherapy.37-40 MDR is discussed further in detail on the next page. Thus, this treatment may 
not completely eradicate the tumor, and cancer patients may relapse after chemotherapy is over.36  
Multidrug Drug Resistance (MDR): 
The evolution of multidrug resistance (MDR) or chemotherapeutic resistance in melanoma 
and most cancers has become a significant challenge to successful chemotherapy. It is a complex 
process that results from the alteration of drug targets and combines multifaceted non-cellular and 
cellular-based mechanisms. MDR can occur in cancer cells by various mechanisms, including 
suppression of apoptosis (cell death inhibition), modifications on agent's metabolism (including at 
the cellular level, e.g., exocytosis), and enhanced DNA repair.41, 42 Due to these MDR abilities, the 
chemotherapy of cells with MDR is challenging. Temozolomide, vinblastine, and Dacarbazine 
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(DTIC) are the most common drugs that are known to be of use in chemotherapy for malignant 
melanoma treatment. However, a meager response rate is reported. The response rates to 
temozolomide, vinblastine, and DTIC were 28%, 9.5%, and 7%, respectively, with 64 patients 
having been reported in a clinical trial.43 Prospective chemotherapy needs to overcome the 
problems described above: MDR and side effects, to improve the patient's quality of life as well 
as to increase the drug efficacy. To completely eradicate the tumor, it is mandatory to overcome 
the problem of MDR.  A simple method to solve the problem of MDR is to increase the amount 
(dose) of anti-cancer drugs that are delivered to the tumor areas so that they can override the MDR 
of tumors. However, merely increasing the dose of drugs causes an increase in the risk of resulting 
severe side effects. Therefore, instead of increasing the overall treatment of antitumor drugs, it is 
necessary to improve delivery and develop materials that show less MDR.  
1.2.2 Nanoparticles-Assisted Chemotherapy 
MDR is a significant obstacle to the successful application of current melanoma therapies. 
It is a crucial factor in relapse and metastasis of melanoma. To surmount this problem, 
nanocarriers-based drug delivery systems have been established as novel strategies for overcoming 
MDR. They have significant advantages that targeted tumors and as a result affected the well-
controlled release of drugs.  Melanoma researchers over the past two decades have reached the 
point where they smartly designed nanoparticles with tumor targeting ligands. These preferentially 
accumulate within the tumor region through active and passive targeting to overcome MDR, which 
can aid successful chemotherapy (Figure 8). Several nanoparticulate drug delivery systems have 
been reported for nanoparticle assisted chemotherapy. DOX and PTX are the two clinically 
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approved drugs with altered biodistribution.44 Liposomes45, Micelles46, dendrimers47, polymer-
drug conjugates48, and nanoparticles44, 49 are the most commonly used nanoparticles for drug 
delivery. Drugs loaded into nanoparticles improved biodistribution and pharmacokinetic 
profiles.44 Nanoparticles-drug delivery systems provide a promising solution that allows 
simultaneous targeting for delivering more than one agent simultaneously at the cellular level. 
Primarily, the ideal nanoparticles should rapidly accumulate within targeted cells. This can be 
obtained by functionalizing the surface of the nanoparticles with specific targeted molecules. 
Among these nanoparticles, polymeric-based drug delivery platforms have attracted much 
attention in recent years. This is attributed to their easy preparation, surface properties, and 
potential for surface modification. Their tumor accumulation relies on targeting of cancer cells 
through active targeting (ligand-receptor interaction) or passive targeting by accumulation in the 
tumor cells via the enhanced permeability and retention (EPR) effect. 
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Figure 8: Schematic illustration of suggested mechanisms in vivo of limited targeting of 
nanoparticles on a cell membrane of healthy cells (Right) vs. extensive targeting of cancer cells on 
the mechanism of active targeting (bottom left) or can be achieved on the mechanism of passive 
targeting by accumulation in the tumor cells via the enhanced permeability and retention effect 
(EPR) (top left).  
1.2.3 Nanoparticles-Assisted Photodynamic Therapy (PDT) 
Photodynamic therapy (PDT) is a well-established treatment procedure for plenty of 
diseases and localized cancer, including melanoma. The mechanism involves the systemic or 
topical administration of photosensitizer drug, along with application of light to the target site, 
which causes photo-damage and subsequent tumor cell death (Figure 9). While PDT is minimally 
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invasive, untargeted photosensitizers distribute throughout the patients body, resulting in 
undesirable adverse effects. 50, 51 
 
Figure 9:Schematic representation of target-activated PDT agents by a specific wavelength, in 
which the therapeutic agent is a photosensitizer (PS).  
 
A research study reports a development that modulates the phototherapeutic performance 
of hybrid π-conjugated organic semiconductor PCPDTBT (SPNs). SPNs are self-regulated NIR – 
absorbing/emitting PDT's efficacy for cancer therapy optimization in vitro (Figure 10). These 
SPNs consist of two-components: the nanostructures and the nanoceria. Nanostructures serve as 
NIR–absorbing/emitting organic semiconducting polymers. Nanoceria, on the other hand, serves 
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as a smart intraparticle regulator that increases/decreases levels of reactive oxygen species (ROS) 
production. In a murine mouse model, nanoceria-doped SPNs under NIR laser irradiation at 808 
nm, this not only leads to significantly enhanced PDT efficacy but also results in minimum damage 
towards healthy tissue.52 
 
Figure 10: Schematic illustrations of nanoceria-doped SPNs under NIR laser irradiation 
(reproduced from reference).52 
1.2.4 Nanoparticles-Assisted Chemodynamic Therapy (CDT) 
In recent years, a lot of effort has been devoted to the development of reactive oxygen 
species (ROS)-dependent anticancer therapies53-56, including chemodynamic therapy (CDT).57-59 
CDT generates ROS by converting endogenous hydrogen peroxide (H2O2) that is abundant in the 
tumor microenvironment (TME)60 into hydroxyl radicals (•OH), which kills tumor cells 
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efficiently.61-66 The mechanism of ROS formation proceeds through the iron-mediated Fenton 
reaction.67 Several nanoparticulate iron delivery systems have been reported for ferroptosis 
assisted CDT, including iron-based68-76, lipid-based (NP coating to solubilize IONPs, or micelles) 
66, 70, 77, 78, silica-based 76, 79, 80, or metal-organic framework derived.68, 70 Iron oxide nanoparticles 
(IONPs) require acidic conditions to disproportionate H2O2 into 
•OH, thus cellular internalization 
through lysosomal pathways is desirable.81 Silica-based nanoparticles can be either decorated with 
cargo for iron delivery or iron oxide nanoparticles can be loaded into the silica core. Similarly, 
polymer-based nanoparticles76, including iron, are loaded into the core.  
Nanoparticles  tend to remain longer inside tumor cells once internalized due to the lower 
exocytosis rates compared to small molecule drugs.82-84 Targeted nanoparticles can thus be used 
to deliver chemotherapeutic agents with the expectation of reduced MDR85, reduced side effects86, 
87, and increased treatment efficacy.87  
While there is a breadth of nanocarriers for delivery of iron available, only a few have 
tumor-targeting functionality built-in. These iron delivery nanomaterials thus typically exhibit 
nonspecific action and may cause significant side effects when applied in vivo, with delivery 
mainly through the enhanced permeability and retention (EPR) effect.57, 59, 76 The internalization 
pathway is often not well controlled, although the size of the nanoparticles typically falls in the 
10−50 nm range for which endocytosis is common.88 We alleviate these issues herein by designing 
conjugated polymer nanoparticles (CPNPs) for receptor-mediated endocytosis, which both 
increases specificity and control of internalization compared to previously reported nanoparticle 
iron delivery systems. We demonstrate this herein for the case study of melanoma by conjugation 
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CPNPs with endothelin-3 (EDN3), which specifically binds with the melanoma endothelin-B 
receptors (EDNRB). The CDT effect of our CPNPs is comparable with published iron delivery 
nanoparticle platforms. 
Ferroptosis: 
Ferroptosis is an iron-dependent form of non-apoptotic regulated cell death, first identified 
by Stockwell et al. in 2012.89 It is biochemically, morphologically, and genetically distinct from 
apoptosis, a popular form of regulated cell death by producing highly toxic •OH though a Fenton 
reaction.90-92 It has, therefore, been hypothesized that therapeutic doses of iron could selectively 
suppress cancer cell growth while leaving healthy cells unharmed 90-93, but the approach has 
remained mostly unexplored.92, 94, 95 Due to mitochondrial malfunction as a significant source of 
H2O2 and metabolic activity, cancer cells produce a high level of  H2O2 compared to normal cells.
96-
101 A high concentration of H2O2 can react with iron in the acidic environment and produce highly 
toxic •OH through a Fenton reaction.102 The result •OH do not diffuse from generation sites due to 
high reactivity and a short half-life (10-9s) but instead oxidize any surrounding bio-
macromolecules very rapidly.103 Two factors that facilitate the selective killing of cancer cells are 
the level of H2O2 generation and overexpression of the receptor-ligand interaction located on the 
cell surface. Among various iron oxide nanoparticles that have been cited for cancer therapy95, 104-
106, a study steered by researchers at the Stanford University School of Medicine (SUSM), 
accidentally discovered that ultrasmall Ferumoxytol (Feraheme™), an iron oxide nanoparticle 
with a diameter of  less than 5 nm invented over 10 years ago. FDA approved in 2009 and 
commercially launched by AMAG Pharmaceuticals, Inc. in the U.S., Ferumoxytol is widely used 
in  chronic kidney disease (CKD) patients to treat iron deficiency in adult and to light up tumors 
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so surgeons can see where to cut. It can deliver iron-loaded nanoparticles into tumors, thus 
increasing their anticancer efficacy. After only 24-48 h of exposure time, high doses of these 
peptide-coated nanoparticles cause a “wave of destruction,” via ferroptosis , making this as a novel 
and reactive pathway for melanoma treatment.104 Researchers at SUSM sought to, more 
definitively, identify the mechanism of a suppressive effect on a broad panel of cancer metastasis 
in mice. The researchers then examined whether melanoma death is iron-dependent, a known 
ferroptosis requirement. Collectively, through several examinations, the SUSM researchers 
demonstrated that the process of cell death was occurring via ferroptosis, a distinct form of 
programmed cell death that differs from other forms, such as apoptosis, necroptosis, and autosis. 
Taken together, the foregoing data determined that nanoparticles treated with an iron chelator, 
deferoxamine (DFO), almost entirely inhibited cell death, suggesting that iron-loaded 
nanoparticles may engage ferroptosis in cells. Moreover, in their findings, surface-modifications 
of nanoparticles with cancer-targeting aMSH peptides, triggered cellular internalization. 
Interestingly, they also determined that ferroptosis in the cell lines occurred with no requirement 
of surface modification with aMSH and delivery occurred through the accumulation of the 
nanoparticles within tumors via leakiness of tumor vasculature due to the EPR effect. 
Other studies report that altering iron metabolism is a well-founded path for cancer 
therapy.107 For improved therapeutic efficacy in nitroquinoline-oxide (NQO)-overexpressing 
tumor cells, a study reports that SPION-micelles with an encapsulated anticancer drug (β-lap) were 
internalized into acidic organelles. The H2O2 generated from β-lap reacts with iron released from 
the micelles in a pH-dependent manner to produce •OH through a Fenton reaction, which can 
oxidize any surrounding, as shown in Figure 11.  
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Figure 11: Schematic illustration of intracellular distribution of SPION-micelles, followed by iron 
release, which is then involved in a Fenton reaction in the presence of H2O2 that is generated from 
β-lap (reproduced from reference).107 
 
An iron nanoparticle conjugated with folic acid was prepared with an average 
hydrodynamic diameter of 244.6 nm.94 Within cells in an acidic environment such as that found in 
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cancer tissue, iron releases from the nanoparticle very rapidly. Later, iron reacts with the high 
levels of H2O2, thus produced by mitochondria mainly found in cancer cells. The resulting highly 
toxic •OH generated through a Fenton reaction can oxidize proteins, lipids, and DNA. This 
treatment decreases malignant cell viability with no noticeable effect of a normal cell, as illustrated 
in Figure 12.  
 
Figure 12:Schematic illustration of the damage of cancer cells occurred via rMOF-FA 
nanoparticles (reproduced from reference).94 
 
Another study has presented a new therapeutic tool to treat cancer cells through luteinizing 
hormone-releasing hormone (LHRH) peptide coated FePt NPs. The controlled release of iron 
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within cells in an acidic environment catalyzes H2O2 to produce reactive oxygen species (ROS), 
which are toxic to tumor cells, as illustrated in Figure 13.108  
 
Figure 13: Schematic illustration internalized of the LHRH peptide coated FePt NPs, causing 
oxidative damages to proteins, lipids, and DNA (reproduced from reference).108  
 
Another study hypothesized that ferroptosis could be significantly enhanced by increasing 
the concentrations of all raw materials involved in the Fenton reaction, such as Fe3+, Fe2+, and 
H2O2. This study concluded that the acceleration of Fenton reaction inside cells generates ROS 
that induce cancer cell death, as shown in Figure 14.109 
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Figure 14: Schematic illustrating the design and synthesis of magnetic nanoparticles which is then 
involved in a Fenton reaction in the presence of H2O2 (reproduced from reference).
109 
 
Another research study reports the toxicity mechanism induced by nanoparticles that 
contain iron and/or other metal ions, thus involved in a Fenton reaction. The study compared 
internalization mechanisms of the nanoparticles when they enter cells in two approaches: 
endocytosis-free nanoparticles, and through active internalization. This study concluded that an 
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endocytosis pathway where nanoparticles rapidly end up confined in lysosomes might result in 
more release of relatively toxic ions (e.g., Fe2+/3+, Cd2+, Ag+, and Au1+/3+ ions) in the acidic 
environment. As a result, increased ROS levels through ferroptosis or apoptosis mechanisms, thus 
cause  DNA and membrane damages, as illustrated in Figure 15.81, 88  
 
Figure 15: Schematic illustration of endocytosis-free nanoparticles vs. active mechanisms 
internalized into the cells (reproduced from reference).88 
1.3 Scope of Reported Dissertation Research 
We aimed to eradicate melanoma cancer cells in vitro. With the developed targeted CPNPs, 
we had success in suppressing tumor cell count, whereas untargeted CPNPs did not show much 
killing effect of the utilized cancer cells. This novel tumor-targeted (CPNP) system was prepared 
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from poly [2,1,3-benzothiadiazole-4,7-diyl [4,4-bis (2-ethylhexyl) - 4H-cyclopenta [2,1-b:3,4-b’] 
dithiophene-2,6-diyl]] (PCPDTBT). The CPNPs are around 62 nm in size, tumor-targeting, and 
deliver iron (as Fe3+) to the intracellular environment to trigger ferroptosis, followed by tumor cell 
death (Figure 16). In my dissertation, I focus on the improvement of a CPNP formulation. To 
improve its efficacy, I focused on the most critical factor, which is the cellular uptake efficiency, 
which occurs through two essential characteristics: 
First, the surface properties, such as charge, of the CPNPs is a factor influencing cellular 
uptake efficiency. The higher the negative charge, the higher the cellular uptake, because the 
melanoma cell membrane is positively charged. The relationship between the CPNP’s surface and 
the cellular uptake is further discussed in chapter four. 
The second factor in increasing uptake is to add some targeting moieties on the CPNP 
surface to increase the chance of receptor-mediated endocytosis. Cells that are expressing high 
amounts of EDNRB on the membrane surface can uptake more ligand coated CPNPs than 
uncoated. 
To analyze these factors, we utilize various analytical methods. The CPNPs are measured 
using dynamic light scattering (DLS), which gives data on their hydrodynamic size, size 
distribution, and the zeta potential. Meanwhile, scanning transmission electron microscopy 
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(STEM) and transmission electron microscopy (TEM) were utilized to evaluate the size uniformity 
of the CPNPs and their location in the cells in the dried state. 
 
Figure 16: Schematic illustrating the biological significance of the Fenton and Haber–Weiss 
reactions. In the presence of Fe3+ (delivered by EDN3-CPNPs) the Haber-Weiss reaction produces 
Fe2+ for the Fenton reaction, in which sufficiently elevated H2O2 in tumor cells is reduced to the 
highly reactive hydroxyl radical and molecular oxygen is returned as a product. 
 
For the case study of melanoma, we found that our endothelin-3 modified CPNPs (EDN3-
CPNPs) encapsulating iron appropriately targeted melanoma tumor cells, resulted in effective 
CDT, and this finally resulted in the increased killing of tumor cells compared to untargeted 
CPNPs. We compared the uptake of EDN3-CPNPs to CPNPs and their main difference was in the 
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internalization efficacy. The EDN3-CPNPs showed a rapid internalization of melanoma cells and, 
therefore, the rapid releasing of iron.  
Conversely, unmodified CPNP uptake across the studied cell lines is suggested to be 
possible due to the attractive interaction of the anionic CPNPs with the relatively positively 
charged EDNRB receptors with less CDT effect in most cases. Besides, untargeted CPNPs showed 
a negligible impact on the intracellular environments of healthy cells due to the absence of 
endothelin-B receptors (EDNRB). 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Introduction 
To make the iron-carrying nanoparticles used in therapeutics more effective towards curing 
the melanoma cancer, it is necessary to understand how it works in the human body. To fully 
understand this, it is fundamental to find out its functional properties and mode of action in vitro 
before introducing them in vivo. This was obtained by growing cell lines in the lab under controlled 
conditions and conducting experiments on them for in vitro studies. Conjugated polymer 
nanoparticles (CPNPs) carrying iron as a CDT tool were fabricated, characterized, and observed 
significant efficacy in targeting and treatment. Functionalization of nanoparticles with endothelin-
3 as targeting agents towards melanoma endothelin-B receptors (EDNRB) expressing cell lines 
was achieved to make CDT targeted, thus reducing the side effects by avoiding uptake in healthy 
cells. Nanoparticle-based iron delivery systems contribute to a significant treatment for various 
cancers. Also, they provide other advantages such as protection from degradation, controlled 
release of encapsulated iron into tumor sites, increased circulation time, and potent tumor-targeted 
efficacy. The nanoparticle-encapsulated iron has a broad range of solubility with significantly 
enhanced cell cytotoxicity. Among these, conjugated polymer-based nanoparticles (CPNPs) 
demonstrate promising activity against melanoma. The cell viability rate of our CPNPs after CDT 
was quantified by MTS assay, which is discussed in detail here within. Cell morphology was 
observed by Transmission Electron Microscopy (TEM) and Scanning Transmission Electron 
Microscopy (STEM). The hydrodynamic diameters and zeta potential of the synthesized CPNPs 
and EDN3-CPNPs were determined by dynamic light scattering (DLS). UV-Vis and Fluorescence 
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spectroscopies were performed to confirm the formation of nanoparticles. All the experimental 
details have been discussed in the following subsections.  
2.2 Materials 
All reagents were purchased from common commercial sources. The reagents were used 
without further purification unless otherwise stated. Poly [2,1,3-benzothiadiazole-4,7-diyl [4,4-bis 
(2-ethylhexyl)-4H-cyclopenta [2,1-b:3,4-b’] dithiophene-2,6-diyl]] (PCPDTBT) with a molecular 
weight 41 000 g/mol was purchased from 1-Material Inc. The polymer was purified to remove low 
molecular weight polymers. Comb-like polymer (SEOCOOH comb) polystyrene–graft–[poly 
(ethyleneoxide),carboxylic-acidend-functionalized] (PS-PEO-COOH) with a molecular weight of 
36 500 g/mol (average Mn, PDI 1.3, Mw 47,450 g/mol) was purchased from Polymer Source Inc. 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), endothelin 3 (human, rat), N-
Hydroxysuccinimide (NHS), Iron (III) chloride, and ferrozine (3-(2-pyridyl)-5,6-diphenyl-1,2,4-
triazine-4′,4″-disulfonic acid sodium salt) were purchased from Sigma-Aldrich. THF 
(tetrahydrofuran, Drisolv) was purchased from EMD Millipore. Acetate Buffer, pH 4.5 was 
purchased from Ricca Chemical. Sodium L-Ascorbate was purchased from TCI. Neocuproine 
(2,9-Dimethyl-1,10-phenanthroline, DMPHEN) was purchased from Alfa Aesar. Hydrochloric 
acid 37%, was purchased from Acros Organics. 
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2.3 Nanoparticle Fabrication 
2.3.1 Purification of PCPDTBT Polymer 
To purify PCPDTBT,6 mL of HPLC grade acetone was added to 3 mg of the polymer in a 
vial. This vial was then heated gently on a hot plate at a low temperature of 20 °C for 15 min. The 
low molecular weight PCPDTBT remained in the supernatant, while the high molecular weight 
settled at the bottom. To the settled PCPDTBT, a small amount of approximately 3 mL of 
chloroform was added. A green solution was observed immediately. To this solution, acetone was 
added in a 1:5 ratio of chloroform to acetone. To protect the solution from the light, the suspension 
was transferred to a foil-wrapped 50 mL centrifuge tube. Amicon Ultra-15 centrifugal filters with 
a molecular weight cutoff of 10 000 kDa were used for filtration. The suspension was centrifuged 
at 4000 rpm for 10 min at 20 °C. The supernatant was removed by micropipette, and the procedure 
was repeated until the supernatant showed a light green color (around four repetitions). The 
purified PCPDTBT was then dried overnight at room temperature before being subjected to CPNPs 
fabrication. 
2.3.2 Purification of PTB7 Polymer 
Before using to make nanoparticles, PTB7 polymer was first purified to remove low 
molecular weight impurities. 3mg of PTB7 was added to a vial with 6 mL of acetone (EMD 
Millipore) and heated gently on a hot plate at 50 ⁰C for 30 min.  The supernatant of this solution 
was removed by micropipette, and the remaining settled at the bottom of the tube was transferred 
to a 50 mL centrifuge tube.  6 mL of chloroform (EMD Millipore) was added, followed by 15 mL 
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of acetone. This mixture was centrifuged (Eppendorf 5810 R) for 10 min at 4000 rpm. The 
supernatant of this mixture was removed, 15 mL of acetone was then added, followed by 3 mL of 
chloroform. The solution was again centrifuged at 4000 rpm for 10 min. This process of 
supernatant removal and addition of acetone and chloroform was repeated twice.  After the final 
supernatant was removed, the remaining settled was left in a fume hood, so trace amounts of 
solvent would evaporate. 
2.3.3 Fabrication of CPNPs Obtained from PCPDTBT Polymer 
To obtain a 0.1 mg/mL stock solution of PCPDTBT, 1 mg of purified polymer was 
dissolved in 10 mL of THF, stirred, and heated at 60 °C for 2 h. The polymer solution was then 
filtered through a PTFE membrane filter with a 0.2 μm pore size before adding a stock solution. 
In contrast, to obtain a 0.02 mg/mL stock solution of PS−PEO−COOH, 1 mg of this polymer was 
dissolved in 50 mL of THF. Approximately a 23:1 molar ratio solution of PCPDTBT to 
PS−PEO−COOH was prepared by adding 10 mL of PCPDTBT stock solution to 2.3 mL of 
PS−PEO−COOH stock solution. This mixture was then gently stirred at room temperature for 
about 30 min. Under vigorous stirring, 1 mL of this mixture was quickly injected into 6 mL of DI 
water. After injection, stirring was stopped immediately. The THF solvent was then removed under 
vacuum at room temperature for up to 3 days. 
Molarity Calculation 
1. PCPDTBT  
PCPDTBT molecular weight, M.wt = 41 000 g/mole 
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No. of moles (n) = Wt. (g) / M.wt (g / mole) 
M = n / v (L)      
M diluted = 4.0 × 10
−8 mole / L    
      = 2.44 × 10−6 M (concentration of undiluted PCPDTBT {stock solution})     
2. PS-PEO-COOH 
PS-PEO-COOH molecular weight, M.wt = 47 450 g/mole                                                            
n = wt. (g) / M.wt (g/mole)                                                                                            
M = 4.2 × 10−7 mole/L (stock concentration of PS-PEO-COOH (1 mg / 50 mL THF) 
3. Mixture of PCPDTBT (10 mL) + PS-PEO-COOH (2.5 mL) 
4. Molar ratio PCPDTBT (M dilute) in 12.5 mL to PS-PEO-COOH (M dilute) in 12.5 mL 
                                     2.0 × 10-6                                    0.084 × 10-6                
            2.0 / 0.084 = 23  
Molar ratio 23:1 PCPDTBT: PS-PEO-COOH in 12.5 mL sol. 
5. Total mass calculation in EDN3-CPNPs 
Total = 6.12 × 10-4 mg/mL of PS-PEO-COOH + 1.34 × 10-2 mg/mL of PCPDTBT + 
3.38 ×10-4 mg/mL of EDN-3 
            Mass of EDN3-CPNPs = 14 µg/mL in water       
2.3.4 Fabrication of CPNPs Obtained from PTB7 Polymer 
PS-PEO-COOH:PTB7 nanoparticles were prepared using the reprecipitation method.  
Approximately 1 mg of PTB7 was dissolved in 3 mL of THF (EMD Millipore) and stirred at 200 
rpm for 2 h at 50 °C. Then, the solution was filtered through a 0.2 micrometer nylon syringe filter 
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(VWR).  Enough PS-PEO-COOH was added to bring the molar ratio of PS-PEO-COOH and PTB7 
to the desired molar ratio.  A portion of this solution was removed, and its volume adjusted, so the 
concentration of PTB7 in solution was 0.1 mg/mL, then left in a tightly sealed vial for a minimum 
of 2 h while stirring to allow both polymers to dissolve completely.  A gas-tight syringe removed 
1 mL of this solution with a beveled tip. Prior to injecting the solution, any bubbles drawn into the 
syringe were removed.  The solution was injected by hand at the fastest rate possible into a narrow 
glass vial containing 5 mL of water stirred at the 1500 rpm. After injection, stirring was 
immediately stopped, and the stir bar was removed. THF was allowed to evaporate from the 
solution in a fume hood.  Size distribution measurements for the nanoparticles were obtained using 
dynamic light scattering (Malvern Nano ZS90). 
2.4 Bioconjugation of CPNPs Obtained from PCPDTBT 
To chemically link endothelin-3 (human, rat) to the CPNPs, the carboxylic groups 
(−COOH) at the nanoparticle surface were first activated with EDC-NHS in the dark at room 
temperature. Then, 200 μL of EDC solution (1mg in 10 mL of DI water) was added to 12 mL of 
CPNPs, and the mixture was stirred gently for 5 min. Next, 100 μL of NHS solution (1 mg in 10 
mL DI water) was added, and the mixture was stirred for another 30 min. Finally, 350 μL of a 
freshly prepared solution of endothelin-3 (human, rat) was added, and the mixture was stirred for 
12 h. The molar ratio of PS−PEO−COOH to EDN3 was 1:10, while the molar ratio of 
PS−PEO−COOH to EDC-NHS was 1:100. These functionalized nanoparticles (EDN3-CPNPs) 
were purified by centrifugal filtration. 
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To remove any unreacted EDN3, NHS, and EDC from the obtained nanoparticle 
suspension, 12 mL of EDN3-CPNPs was filtered by centrifugal filtration. Amicon Ultra-15 
centrifugal filters with the molecular weight cutoff 30 000 kDa were used for filtration. The 
nanoparticle solution was spun at 2000 rpm at 20 °C in a swinging bucket rotor for 6 min. For 
complete removal of unreacted NHS, EDC, and EDN3 from the EDN3-CPNPs solution, two 
filtrations were needed. After each filtration cycle, approximately 6 mL of filtrate was removed, 
and the volume of the EDN3-CPNPs suspension was adjusted back to 12 mL by adding a complete 
growth medium. 
2.5 Bioconjugation of CPNPs Obtained from PTB7 
PTB7 nanoparticles were functionalized by first adding EDC (Sigma Aldrich) to the 
solution in at a ratio of 1 mole PS-PEO-COOH for every 10 moles of EDC. The solution was 
stirred at room temperature for 15 min before NHS (Sigma Aldrich) was added at a ratio of 1 mole 
PS-PEO-COOH for every 10 moles NHS.  After 15 min, endothelin-3 (Sigma Aldrich) was added 
to the solution at the ratio of 1 mole PS-PEO-COOH for every 5 moles of endothelin-3. The 
solution was stirred for 2 h and then purified by centrifuging the solution using a nylon centrifugal 
filter with a molecular weight cutoff 50 000 kDa (EMD Millipore).   
Centrifugal filtration was carried out by spinning the solutions at rates between 1500 and 
2000 rpm to reduce the volume to 10% of its original volume while attempting to minimize the 
aggregation of the nanoparticles. DI water was then used to bring the solution back to its original 
volume. This process has repeated a minimum of 4 times per solution. After the final round of 
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centrifugal filtration, the concentrated solution was not adjusted back to its original volume and 
instead saved in a concentrated form for further use. 
An alternative purification approach was investigated but never used for cell studies using 
dialysis membranes with a 50 000 kDa molecular cutoff (Spectrum Labs).  Solutions were loaded 
into five floating dialysis membranes and suspended in 500 mL of DI water.  The solutions were 
left in a fridge for 24 h to prevent the breakdown of the peptides. This procedure was repeated four 
times without removing the solution from the dialysis membrane.   
2.6 Characterization of Nanoparticles 
2.6.1 UV-Vis Spectroscopy 
Absorption spectroscopy on nanoparticle suspensions in water and the raw polymer 
material (PCPDTBT) in THF was completed with a 1 cm path length quartz cuvette using an 
Agilent 8453 spectrophotometer. We kept the absorbance below 1 to keep within the linear range 
of Beer’s law. 
2.6.2 Fluorescence Spectroscopy 
Fluorescence emission spectra were collected following absorption spectroscopy in the 
same 1 cm path length quartz cuvette with a Nanolog Horiba Jobin Yvon Fluorimeter. Their 
parameter settings are 687 nm excitation wavelength, slit width 5 nm, and emission wavelength 
712-950 nm, slit width 5nm. 
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2.6.3 Fourier-Transform Infrared Spectroscopy 
The powders of PCPDTBT, PS−PEO−COOH, CPNPs, and EDN3-CPNPs were 
characterized by IR spectroscopy. The CPNPs and EDN3-CPNPs were frozen in DI water and 
lyophilized (freeze-dried) using a FreeZone 4.5 L Freeze-Dry System (Labconco) prior to analysis. 
All measurements were acquired over the range 600−3500 cm−1 on a PerkinElmer Spectrum 100 
FTIR spectrometer. 
2.6.4 Dynamic Light Scattering (DLS) 
The hydrodynamic diameters of the synthesized CPNPs and EDN3-CPNPs were 
determined by dynamic light scattering using a Zeta Particle Size Analyzer (Nano-ZS, Malvern 
Instrument).1 mL sample added to the appropriate cuvette without touching transparent areas.  
2.6.5 Transmission Electron Microscopy (TEM) 
The particle size was also determined by TEM (FEI Tecnai F30 TEM (300 kV) and JEOL 
TEM-1011 (100 kV)). The TEM grids used were C-flat 1 μm 200 mesh (cat. no. CF21-50) 
purchased from Electron Microscopy Sciences. About 2-3 µL was pipetted onto a TEM grid and 
dried under vacuum.  
2.6.6 Scanning Transmission Electron Microscopy (STEM) 
STEM observations were conducted on a Zeiss ULTRA-55 FEG SEM (Zeiss, 30 kV) to 
analyze the size of functionalized nanoparticles. The TEM grids used were C-flat 1 μm 300 mesh 
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(cat. no. CF31-50) purchased from Electron Microscopy Sciences. About 2-3 µL was pipetted onto 
a TEM grid and dried under vacuum.  
2.7 Cell Culture 
Cell lines were acquired from the American Tissue Culture Center (ATCC), Malme-3M (a 
malignant human melanoma cell line) (at fifth passage) was cultured in Dulbecco’s modified 
Eagle’s medium (DMEM), Ham’s F-12 media supplemented with 20% heat-inactivated fetal 
bovine serum (FBS), 1% penicillin−streptomycin, and L-glutamine (100×), all purchased from 
Corning. A375 (at fourth passage) and SK-Mel-28 (at second passage) (human melanoma cell 
lines), AML 12 (mouse liver cell line, noncancerous) (at third passage), Hepa 1−6 (mouse liver 
cell line, cancerous) (at third passage), and the human urinary bladder cancerous T24 cell line (at 
fourth passage) were cultured in DMEM medium supplemented with 10% FBS. Cells were grown 
under standard conditions for 24 h at 37 °C in a humidified incubator in an atmosphere of 5% CO2 
and 95% air in a T-75 flask for 4−7 days to reach a confluence of 70−80% before being subjected 
to any further experimentation. 
2.7.1 Cell Viability Determination by MTS Assay (PCPDTBT) 
In vitro cell viability was determined with the CellTiter 96® AQueous One Solution 
Reagent, which contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS]. Cells in known volume were 
counted using a hemocytometer. All cells were seeded in 96-well plate with a density of 10 000 
cells/well and incubated under standard conditions for 24 h prior to MTS assay. The medium was 
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removed entirely, and the cells were thoroughly washed with 100 µL fresh medium. The medium 
was then replaced with another 100 µL fresh medium containing appropriate doses (14, 1.4, 0.14, 
and 0.014 µg/mL) of CPNPs and EDN3-CPNPs, respectively along with control experiment (0 
mg/mL) for 24 h. Subsequently, wells were carefully washed twice with fresh medium to remove 
any uninternalized nanoparticles. The assay was then performed by adding 20 μL of the CellTiter 
96 AQueous One Solution Reagent (purchased from Promega) per well. The absorbance was 
recorded at 490 nm on BioTek ELx808 absorbance microplate reader at time 0 to determine the 
background signal. The plates were then incubated again for up to 1−4 h protected from light. 
Absorbance was then rerecorded at the same wavelength indicated above. All experiments were 
performed in triplicate. The cell viability (%) was calculated by the following formula, where [A] 
is the average absorbance:110, 111 
Cell viability (%) =  
[A]490 (sample (treated cells))−[A]490 (blank (no cells))
[A]490 (control (untreated cells))−[A]490 (blank (no cells))
 × 100 ( 1 ) 
Statistical analysis was performed on the data presented in chapter 4. A two-tailed 
Student’s t test was used to assess the significant differences between cell viability values observed 
for nontargeted and targeted CPNPs. A p-value < 0.05 was considered statistically significant. 
Outcomes were indicated as *P < 0.05 and **P < 0.01. 
2.7.2 PDT and Cell Viability Determination by MTS Assay (PTB7) 
100 µL of a given cell line was plated into a well at a density of 500 000 cells/mL.  After 
being given one day to grow with normal media, the media in each well was then changed to 
DMEM with FBS or DMEM only.  100 µL of either unfunctionalized nanoparticles, functionalized 
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nanoparticles, or media only was added to the wells and incubated for another 24 h. After this 
period, the media in each well was again changed. 
To assess the effect of light on the cell lines incubated with nanoparticles, well plates with 
cell lines were removed from the incubator and exposed to the maximum power of a solar simulator 
for 1 h.  The cells were then put back into the incubator for 4 h. After the 4-h incubation period, 
an MTS assay (Promega) was performed according to manufacturer provided protocol, absorbance 
measured at 490 nm using a Biotek ELY 808 plate reader as well as a reading at 4 h, the difference 
between the two is used as the reported absorbance due to MTS. 
To evaluate the intrinsic toxicity of these nanoparticles, cells were plated in well plates and 
incubated with the nanoparticles in the same conditions as cells exposed to light. MTS was added 
after the cells had been incubated for 24 h with nanoparticles, and the media had been changed. 
2.8 Quantitation of Amount of Endothelin Peptide Attached to CPNPs 
BioVision’s Extra Sense BCA Protein Assay Kit was performed to assess the amount of 
endothelin-3 attached per mg of CPNPs. Absorption spectroscopy on the assay was first completed 
in a 1 cm path length quartz cuvette with an Agilent 8453 Spectrophotometer to confirm the 
absorption wavelength (562 nm). The microplate reader (BioTek ELx808) could approach this 
peak absorption with a 570 nm filter. A standard curve was created by plotting the absorbance 
versus different concentrations of the standard solution expressed in μg/mL, bovine serum albumin 
(BSA). Data for the calibration curve were obtained using 8 standard samples consisting of one 
part of a known concentration of (100 μL BSA standard) and 1 part of BCA Working Reagent 
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(100 μL) per well on a 96-well plate. The instructions from the assay kit were followed for the 
quantification. The blank consists of DI water. The standard curve was found to be linear over the 
range of 0−40 μg/mL. The total protein concentration is immediately observable by a color change 
of the sample from green to purple in proportion to the protein concentration. The absorbance was 
measured at a wavelength of 570 nm in a BioTek ELx808 absorbance microplate reader.111, 112 The 
original published protocol was modified for the quantitation of the amount of endothelin peptide 
attached to the CPNPs. 
The assay relies on two chemical reactions: (1) the reduction of cupric ions Cu2+ to cuprous 
ions Cu1+ and (2) the chelation step of one Cu1+ with two BCA molecules, forming an intense 
purple BCA-Cu1+-BCA complex, the intensity of which can be measured spectrophotometrically 
near the maximum absorbance peak 562nm. The amount of complex formed is dependent upon 
the amount of EDN3 in solution to be quantified. The BCA−copper complex was performed on 
96- well plates, which enabled the EDN3 content of a large number of samples to be measured 
simultaneously with the use of a microtiter plate reader. The BCA assay of our protocol consists 
of mixing 1 part of the solution to be quantified (14 µg/mL EDN3-CPNPs sample 150 μL) with 1 
part of the prepared (BCA Working Reagent 150 μL) per well. The net absorbance at 570 nm is 
found by subtracting the absorbance (A570) of the blank from the recorded A570 values for the BSA 
protein standards and EDN3-CPNPs sample. A standard curve created by plotting the net 
absorbance at 570 nm versus the BSA protein standard different concentrations. The obtained 
absorbance is directly proportional to the amount of EDN3 in solution to be quantified. The protein 
concentration of the EDN3-CPNPs sample falls within the working linear range. The protein 
concentration of the sample was determined by comparison with the known protein standard 
 41 
concentrations of BSA. All experiments were performed in triplicate, and 14 µg/mL of unmodified 
CPNPs (without EDN3 on the surface) was applied as a control. 
2.9 Total Quantitation of Iron Content in Nanoparticles 
The iron content in CPNPs was determined using a ferrozine-based spectrophotometric 
iron estimation protocol. Ferrozine is as an effective chelator for ferrous iron, but not ferric iron, 
and assists in forming a Fe2+−ferrozine complex that absorbs strongly at 562 nm.113-116 The original 
published protocol was modified for the quantification of total iron in CPNPs. For this protocol, 
EDN3-CPNPs (5 mL) were dispersed in 1.4 N hydrochloric acid (1 volume nanomaterial/mL) and 
kept for 2 h at 60 °C in a water bath sonicator to allow the mineralization and the complete 
dissolution of the EDN3-CPNPs carrying iron. The iron-detection reagent was prepared from 6.5 
mM ferrozine, 6.5 mM neocuproine, and 1 M ascorbic acid (Figure 17) dissolved in acetate buffer 
at pH 4.5 and sonicated in a bath sonicator to accelerate the dissolution of the ferrozine and 
neocuproine. The resulting yellow-colored solution, 0.5 mL, was then added to 0.5 mL of the 
dissolved nanoparticle solution and the mixture was shaken continuously for 60 min at room 
temperature. Data for the calibration curve were obtained using 8 standard samples consisting of 
one part of a known concentration (FeCl3 standard 100 μL) with 1 part of the prepared Ferrozine 
Working Reagent (100 μL) per well (the total volume loaded per well in a 96-well plate is 200 μL 
in triplicate). The instructions from the assay kit were followed for the quantification. The optical 
density of the sample was measured at 570 nm using a BioTek ELx808 absorbance microplate 
reader. The concentration of the iron was calculated by comparing this value with a calibration 
curve obtained by recording the absorbance of FeCl3 standard solutions in HCl 0.01 N (ranging 
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from 0 to 40 μg/mL). The standard curve was found to be linear over the range of 0−40 μg/mL. 
HCl (0.01 N) with the iron-detection reagent was used as a blank. 
 
Figure 17: Raw materials needed for Iron-detection reagent. 
2.10 Observation of Cellular Uptake and Localization of Nanoparticles by TEM & STEM  
Cells were treated with EDN3-CPNPs (1.4 µg/mL) cultured in 75 cm2 flasks for 24 h. The 
cells were then thoroughly washed with 5 mL of PBS (phosphate-buffered saline) three times 
(purchased from Corning) to remove extracellular nanoparticles. Subsequently, cells were 
trypsinized with 5 mL of 0.25% trypsin and 2.21 mM EDTA, 1× (obtained from Corning), and 
incubated at 37 °C for 15 min. The cell suspension was thoroughly mixed (three times). The cells 
were then settled and collected into a soft pellet. The supernatant was removed using a micropipette 
without removing the settlement at the bottom of the tube. The pellet was washed with HBSS 
(Hank’s Balanced Salt Solution) without phenol red (purchased from Lonza). To the settled cells, 
a small amount of 4% paraformaldehyde obtained from Electron Microscopy Sciences was applied 
for 15 min at room temperature. The cell suspension was thoroughly mixed. The fixed cells were 
then settled and washed with DPBS, Dulbecco’s phosphate-buffered saline (purchased from 
Corning). Then, a small drop of the cell suspension (about 2−3 μL) was pipetted onto a TEM grid 
 
 
 
ferrozine neocuproine ascorbic acid ferric chloride 
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and dried under vacuum. The TEM grids used were C-flat 1 μm 200 mesh (cat. no. CF21−50) and 
300 mesh (cat. no. CF31−50) purchased from Electron Microscopy Sciences. The specimens were 
viewed using transmission electron microscopy [TEM] (JEOL TEM-1011) and scanning 
transmission electron microscopy [STEM] (Zeiss ULTRA-55 FEG SEM). 
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CHAPTER THREE: POLYMERIC NANOPARTICLES OF PTB7 FOR 
PHOTODYNAMIC THERAPY OF MELANOMA SKIN CANCER 
3.1 Introduction 
Photodynamic therapy or PDT offers an effective treatment to combat melanomas. PDT is 
a light-based therapy that uses a sensitizer that is applied to cells, then activated by light that 
releases toxic chemicals to cancer cells or tissues. Often these chemicals are reactive oxygen 
species (ROS) formed by the transfer of energy or an electron to oxygen, allowing for the 
generation of singlet oxygen or other ROS. When ROS reach sufficient concentrations, they induce 
oxidative stress that damages DNA and proteins, eventually leading to cell death, by necrosis or 
apoptosis.117-119  
PDT sensitizers can be either cellular-targeted or non-targeted. Targeted PDT specifically 
affects malignant tumors with minimum effect on healthy cells. Patients receiving the non-targeted 
PDT of Photofrin must avoid sunlight or bright indoor lights for 30 days or more, according to 
FDA recommendation.120 This is attributed to the sensitivity of the skin to light through the 
residual drugs. It has been cited that the nonpolar nature of the Photofrin and many other 
photosensitizers most likely causes this persistence in the skin. 121 Light sensitivity could persist 
for a couple of weeks after treatment is completed according to a study of Japanese patients who 
received PDT.122 To improve patient survival and quality of life in the treatment of melanoma, a 
drug would quickly clear the body while present within targeted cancer cells. Doshi et al. 
demonstrated that water-stable folate – CPNPs are explicitly targeted to ovarian cancer cells while 
having minimal impact on other cell lines.123 The conducting polymers MEHPPV used to prepare 
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Folate-CPNPs to have a maximum absorbance wavelength near 500 nm. Typical skin and 
melanomas have a maximum absorbance wavelength in the range of 500-600 nm.124, 125 The 
overlap of maximum absorbance between the skin and Folate-CPNPs prevents the penetration of 
useful light. This may be a major limiting factor of Folate-CPNPs to melanoma PDT. However, 
conducting polymers thus have absorbance wavelength above 600 nm would be good candidates 
for use in PDT. A photoconductive polymer PTB7 with an absorbance wavelength in the 600-700 
nm range makes it an attractive candidate for targeted PDT, where the absorbance of the skin 
begins to weaken. 
In the work presented here, water-stable CPNPs composed of PTB7 and PS-PEO-COOH 
were prepared using the reprecipitation method. The obtained CPNPs were then functionalized 
with endothelin 3.  
 3.2 Results and Discussion 
3.2.1 Size Measurements 
Figure 18 shows the size measurements of PTB7/PS-PEO-COOH NPs were taken after 
each batch was created. Nanotechnology has shown promise in delivering anticancer drugs, 
reducing side effects, and enhancing efficiency. Many experiments indicated that a nanoparticle 
uptake via receptor-mediated endocytosis, highly depends on the size of the nanoparticles. 126-128 
Most trials recorded an optimal size in the diameter of the nanoparticles, which is approximately 
50 nm at which the highest uptake rate takes place through receptor-mediated endocytosis (RME). 
However, there is also a maximum size reported, which is about 200 nm and beyond, at which the 
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cellular uptake does not occur. Our CPNPs showed an optimized size of around 60 nm in diameter. 
PTB7 derived EDN3-CPNPs, on the other hand, were difficult to handle due to challenges with 
preparation and poor colloidal stability. 
 
Figure 18: Observed z average size distribution for PTB7 NPs. 
3.2.2 MTS Cell Viability Assay without Light 
Malme-3M cells exposed to functionalized PTB7 nanoparticles and unfunctionalized 
PTB7 nanoparticles show no significant difference in viability between the two populations, which 
in turn are both not different from the untreated controls. Functionalized nanoparticles were 
produced with a 2:1 PTB7 to PS-PEO-COOH molar ratio and the cells were grown in DMEM 
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(Figure 19).  It should also be noted that while the Malme-3M cells also appeared to be less viable 
than the cells exposed to only the FBS media, this difference was not significantly different. It is 
possible that there was enough free endothelin-3 in the solutions of functionalized nanoparticles 
to increase the viability of cells that were nutrient-deprived such as those grown in DMEM through 
reduced apoptosis signaling and enhanced proliferation signaling. Conversely, the cells grown in 
FBS would have had normal metabolism and thus could be more susceptible to increased oxidative 
stress induced by internalized nanoparticles.  
In the dark, Malme-3M cells in DMEM were significantly more viable when exposed to 
2:1 functionalized NPs than 2:1 unfunctionalized NPs.  The cells treated with 2:1 unfunctionalized 
NPs were significantly less viable than untreated cells, while Malme-3M cells treated with 2:1 
functionalized NPs were not significantly different than untreated NPs. Malme-3M cells showed 
no significant difference in cell viability between NPs-treated and untreated cells, apart from the 
cells treated with 2:1 unfunctionalized NPs in DMEM. 
When looking at the T24 cell line, it is observed that the cells exposed to 10:1 PTB7: PS-
PEO-COOH NPs in FBS were significantly less viable than the untreated cells. T24 cells exposed 
to 10:1 NPs were not significantly different than untreated cells, cells exposed to 2:1 NPs in either 
DMEM or FBS similarly showed no significant difference in viability from untreated cells. 
T24 showed no difference between untreated and treated cells when cells were treated with 
2:1 NPs. When treated with 10:1 NPs, all cells treated with 10:1 unfunctionalized NPs were 
significantly less viable than untreated cells, while only cells treated with 10:1 functionalized NPs 
in FBS showed significantly reduced viability when compared to untreated cells in FBS. 
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It is possible that T24 cells are more sensitive to PTB7 NPs than Malme-3M cells, it is also 
possible that NPs with 10:1 PTB7 to PS-PEO-COOH ratios have lower surface charge than those 
with a 2:1 ratio making them easier to absorb non-specifically into cells.  
Overall these findings indicate that the PTB7 nanoparticles are not cytotoxic when PDT is 
not being applied. 
 
Figure 19: MTS data for cells with no light exposure.  
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3.2.3 MTS Cell Viability Assay with Light 
For light treated samples, the sample treated with functionalized NPs in DMEM also 
showed no significant difference between the sample treated with unfunctionalized and 
functionalized NPs, and the respective controls (Figure 20). 
 
Figure 20: MTS results for cells with 1 hour of light exposure. 
3.3 Conclusions 
In this work, low band-gap poly ({4,8-bis [(2-ethylhexyl) oxy] benzo [1,2-b:4,5-b′] 
dithiophene-2,6-diyl}{3-fluoro-2-[(2-ethylhexyl) carbonyl] thieno [3,4-b] thiophenediyl}) (PTB7) 
was made into PTB7 nanoparticles by the reprecipitation method. Then the obtained conjugated 
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polymer nanoparticles (CPNPs) were functionalized with the polypeptide endothelin-3 to form 
EDN3-CPNPs, which specifically target melanoma and bladder cells that have overexpression 
endothelin receptor type b on their cells surfaces towards PDT treatment. Taken together, the 
results indicate that our approach was not successful. No significant differences between controls 
and nanoparticle treated samples were found after PDT treatment, and no difference between PDT 
treatment with targeted and untargeted PTB7 nanoparticles was found. These findings are 
attributed to the PTB7 derived EDN3-CPNPs were difficult to handle due to challenges with 
preparation and poor colloidal stability. 
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CHAPTER FOUR: POLYMERIC NANOPARTICLES WITH 
ENCAPSULATED IRON FOR FERROPTOSIS ASSISTED 
CHEMODYNAMIC THERAPY OF MELANOMA SKIN CANCER 
4.1 Introduction 
In this chapter, we report the development and application of novel CPNPs for 
chemodynamic therapy (CDT). The CPNPs carry iron in the core to catalyze the Fenton reaction 
in tumor cells to perform CDT (Figure 21) and are tumor-targeted. The nanoparticle design allows 
for the change of the surface functional groups to target different tumors. The iron in the core of 
our nanoparticles is a serendipitous outcome of the synthetic process that is used to synthesize the 
polymer. Iron is a catalyst in the synthetic process and is not readily removed by purification; we, 
therefore, exploited this advantage in our CPNP-based tumor-targeted CDT. Conjugated polymer 
nanoparticles have received substantial attention for nanomedicine applications129-131, including 
light-activated ROS formation in photodynamic therapy (PDT)56, 123, 132-135, but have not been 
developed for CDT. In work reported herein, the CPNPs carry iron that acts as a catalyst in Fenton 
chemistry to produce ROS from hydrogen peroxide (H2O2) that is endogenous and elevated for 
many types of tumors.61, 62, 65 Unlike the PDT method that also produces ROS, ferroptosis-based 
CDT does not require external activation by light. In addition, although ferroptosis proceeds 
through the formation of ROS, the ROS source is endogenous H2O2, not oxygen. Thus, the 
ferroptosis-based CDT mechanism is not expected to suffer dramatically reduced efficacy in 
hypoxic tumors.136 CDT is, therefore, a promising avenue for the development of a treatment of 
multidrug resistant (MDR) or PDT resistant melanomas, in particular for advanced stages (III-IV) 
of melanoma where conventional methods are not feasible or no longer effective.57, 81, 107, 110 
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Here we report tumor-targeted conjugated polymer nanoparticles prepared from 
PCPDTBT (poly[2,1,3-benzothiadiazole-4,7-diyl[4,4-bis(2-ethylhexyl)-4H-cyclopenta[2,1-b:3,4-
b′] dithiophene-2,6-diyl]]). The CPNPs are around 62 nm in size, tumor-targeted, and deliver iron 
(as Fe3+) to the intracellular environment of tumor cells to trigger ferroptosis-based CDT followed 
by tumor cell death. For the case study of melanoma, we found that our endothelin-3 modified 
CPNPs (EDN3- CPNPs) target melanoma tumor cells and resulted in effective CDT. The results 
of our work with EDN3-CPNPs show enhanced melanoma tumor targeting and tumor cell killing.  
 
Figure 21: The mechanism of ROS formation proceeds through the iron-mediated Fenton reaction. 
 Low band gap conjugated copolymer (poly{[4,4-bis(2-ethylhexyl)-cyclopenta-(2,1-b;3,4-
b′) dithiophen]-2,6-diyl-alt-(2,1,3-benzothiadiazole)−4,7-diyl}) (PCPDTBT) is based on the 
cyclopentadithiophene CPDT (donor) and benzothiadiazole BT (acceptor). The preparation of this 
polymer involves iron (III) chloride as a catalyst, as shown in Figures 22 and Figure 23, 137-140; we, 
therefore, expected the corresponding CPNPs to be rich in iron content. This warranted 
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investigation of their usefulness as a ferroptosis inducing nanomedicine for melanoma CDT as an 
alternative to PDT. 
 
Figure 22: Synthesis of PCPDTBT monomers. 
 
Figure 23: Synthesis of PCPDTBT polymers. 
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CPNPs of this PCPDTBT polymer without further surface modifications were prepared 
recently in aqueous solution using the reprecipitation method Figure 24. The nanoparticles 
exhibited an aqueous stable colloidal dispersion owing to its negatively charged surface (-30 mV) 
with a hydrodynamic diameter of approximately 75 nm. These CPNPs were shown to be 
internalized by macrophages.141  
 
Figure 24: A schematic diagram showing the preparation of low-bandgap polymer-based CPdots 
via reprecipitation method and their UV−Vis absorption and emission spectra (reproduced from 
reference).141 
4.2 Fabrication of CPNPs 
The preparation of PCPDTBT polymer involves iron (III) chloride as a catalyst137, 139, 142, 
143; we, therefore, expected the corresponding CPNPs to be rich in iron content. Difficulties with 
the removal of the iron (III) chloride catalyst from conjugated polymers has been a known issue 
in conjugated polymer plastic solar cells even after multiple purification steps, supporting the 
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reasonableness of our premise.144-148 This warranted investigation of their usefulness as a 
ferroptosis-inducing nanomedicine for antitumor CDT towards otherwise difficult to treat tumors. 
We prepared PCPDTBT/PS-PEO-COOH composite nanoparticles using the reprecipitation 
method; a method described previously149 in which a mixture of PCPDTBT and PS-PEO-COOH 
polymers is dissolved in a good organic solvent (i.e., THF) and then injected rapidly into water 
(poor solvent) under vigorous stirring ( Figure 25 and Figure 26A). The resulting nanoparticles 
have the characteristics of good water dispersibility, low cytotoxicity, and excellent stability in the 
aqueous medium – at least 6 months at 4 ⁰C (vide infra).  
The CPNP was designed to consist of two components: a hydrophobic polymer core and a 
hydrophilic carboxyl corona for further bioconjugation. PS−PEO−COOH itself consists of a 
hydrophobic polystyrene backbone and hydrophilic side chains of ethylene oxide terminated with 
the carboxylic acid. We speculate that throughout the CPNPs formation, the functional groups 
(−COOH) and hydrophilic PEO chains extend outside the CPNPs core into the aqueous 
surroundings, whereas the hydrophobic polystyrene backbones are embedded inside the 
CPNPs.129, 150 The change in ζ potential to a more negative value supports this suggestion. 
Characterization by UV−Vis and fluorescence spectroscopy (Figure 26B, Figure 27, Figure 28, 
and Figure 29), gives a clear indication that nanoparticles were formed. The absorption spectrum 
of molecularly dissolved PCPDTBT in THF as the solvent shows an absorption peak around 721 
nm, while broadened peaks were seen for CPNPs and EDN3-CPNPs with 700 nm absorption 
maximum. The main absorption bands of molecular PCPDTBT are S0 → S1 (λ max = 721 nm) and 
S0 → S2 (λ max = 412 nm). Both are observed in our UV−Vis spectra and correlate with previous 
reports.151, 152 In our work and other publications, the later transition seems less affected by 
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nanoparticle formation, while the first transition is significantly affected.153-155 The spectral 
broadening and blueshift of nanoparticles compared to molecularly dispersed PCPDTBT indicate 
aggregation of the polymer chains into nanoparticles, likely in the form of H-aggregates.153, 154, 156 
The emission peak of molecularly dissolved PCPDTBT in THF was observed at 760 nm, while 
CPNPs and EDN3-CPNPs were found with a significant redshift to 840 and 830 nm, respectively, 
indicating interchain π−π stacking and thus again suggesting nanoparticle formation.154, 156  
 
Figure 25: Schematic illustration of the formation of conjugated polymer nanoparticles carrying 
iron (CPNPs and EDN3-CPNPs).  
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Figure 26: (A) Schematic illustration of the reprecipitation method, a technique in which a solution 
of organic material in a good solvent was injected into a very poor solvent for the organic 
materials.(B) Normalized absorption (blue) and emission (red) spectra of the EDN3-CPNPs in 
water, CPNPs in water, and PCPDTBT in THF. 
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Figure 27: Photoluminescence excitation and emission spectroscopies of PCPDTBT in THF. 
 
Figure 28: Photoluminescence excitation and emission spectroscopies of CPNPs in DI water. 
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Figure 29: Photoluminescence excitation and emission spectroscopies of EDN3-CPNPs in DI 
water. 
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4.3 Bioconjugation of CPNPs  
The choice of the EDN3-targeting ligand was motivated by the fact that endothelin receptor 
B (EDNRB) is overexpressed in most human melanomas and is unique to diseased tissues. The 
EDN axis is accepted to assume a central role in different malignancies, including melanoma, 
central nervous system tumors, prostate, ovarian, cervical and breast.14 Reports indicate that 
EDNRB expression increases in human carcinoma melanoma cells as they progress to the 
metastatic disease state.22, 157 EDNRB is particularly engaging as a target for antibody−drug 
conjugates (ADCs) because of its negligible expression on healthy tissue, localization, and rapid 
endocytosis.158, 159 The receptors recognize their corresponding agonist through complementarity-
determining region loops, specifically between the EDNRB binding pocket and the N-terminal 
amine of EDN3, which is deeply buried within the EDNRB pocket during the interaction (Figure 
32 and Figure 33).25  
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Figure 30: Schematic representation of the interaction of endothelins with their receptors. The 
ligands interact with the receptor through its terminal free carboxylic end group, which is 
unaffected by our coupling chemistry. 
Our strategy for bioconjugation on the surface of CPNPs is based on a carbodiimide-
mediated coupling reaction with EDC and NHS.129, 160 For this method, the EDC/NHS solution 
was added to the CPNPs suspension. The EDN3 peptide solution was then applied. Peptide bonds 
were formed between the free carboxylic end groups of CPNPs with the primary amine groups of 
endothelin 3, producing highly selective nanoparticles for targeting of malignant melanoma 
(Figure 30 and Figure 31). We recognize the need for the N-terminal amine of EDN3 to be avoided 
during conjugation to nanoparticles to allow efficient binding between EDN3 and EDNRB. A 
weakness in our CPNP-EDN3 coupling approach is that the EDC/NHS approach (discussed 
below) indiscriminately couples free amines of EDN3 to the COOH groups on the nanoparticles. 
As a result, it is probable that we obtain EDN3-CPNPs that are heterogeneously decorated. This 
implies that not every EDN3 that is attached to the nanoparticle surface will be effective at 
activating EDNRB. An alternative approach to be explored in future work is to use Lys7 or Lys9 
as sites for CPNPs conjugation with EDN3, since these are away from the EDNRB binding site 
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and exposed to solvents. Such specific conjugation may be feasible by solid-phase peptide 
synthesis, potentially in combination with other conjugation techniques. 
 
Figure 31: Mechanism of bioconjugation the surface of CPNPs by carbodiimide-mediated 
coupling reaction with EDC and NHS. 
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Figure 32: Targeting, cellular uptake of EDN3-CPNPs, and iron release using receptor-mediated 
endocytosis. 
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Figure 33: Schematic representation of the interactions of endothelins with EDNRA binds most 
strongly to EDN1 and EDN2 with a very minimum affinity towards EDN3,  while EDNRB binds 
the EDN1, EDN2, and EDN3 with similar affinities. Amino acids sequence in proteins that are 
identical in both receptors (black circles), different in both receptors (blue circles), identical to 
each other (green circles), only in ETAR (purple circles), and only in ETBR (red circles).   
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We speculate that the internalization mechanism of EDN3-CPNPs into melanoma cells 
correlates with previous reports161-163 and involves the following steps : (I) Initially, EDN3-CPNPs 
internalizes into melanomas (A375, Malme-3M) and human bladder cancer cells (T24) using the 
endocytosis pathway.161 The EDN3-CPNPS transport into the malignant cells via receptor-
mediated endocytosis through overexpression of endothelin receptor-B (EDNRB) present on the 
surface of these cells.162 (II) The EDN3-CPNPS then migrates by fusing cell membranes until they 
reach an early endosome form. (III) They travel along the increasingly acidic endocytic pathway 
(pH range 6.0-5.0) and end up in late endosomes or lysosomes (pH < 5.0).163 (IV) During this 
process the EDN3-CPNPs release iron as Fe(III), which is converted to Fe(II) via the Haber–Weiss 
reaction. The Fe(II) then participates in the Fenton reaction to produce hydroxyl radicals (•OH) 
from H2O2 that is naturally and abundantly present in cancer cells. The resulting 
•OH can rapidly 
oxidize bio-macromolecules, cause damage to DNA, and reduce tumor cell population. (Figure 
32). 
Conjugation of the peptide to CPNPs was analyzed by FTIR; data shown in Figure 34, 
Figure 35, Figure 36, and Figure 37. FTIR spectra of the lyophilized CPNPs and EDN3-CPNPs 
show a broad and strong peak at 3400 cm-1 corresponding to the O–H stretch of hydrogen-bonded 
hydroxyls, while this peak is weak as compared with PS-PEO-COOH. The peak at 1090 cm-1 
belonging to the C–O stretch of hydroxyls suggests the presence of PS-PEO-COOH. The FTIR 
spectra also exhibited that the three peaks at 2850-2958 cm−1 resulted from PCPDTBT attributed 
to C-H bond asymmetric and symmetric stretching vibration. Moreover, the peaks at 1550 and 
1360 cm−1 are due to the asymmetric and symmetric deformation vibration of the C-H bond 
resulted from PCPDTBT, verifying that the CPNPs have been synthesized. Figure 37 shows peaks 
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at 2360, and 2339 cm−1 that are attributed to atmospheric CO2.
164-166 New peaks were also observed 
in the 1750-2250 cm-1 range. These peaks can most likely be attributed to contributions from amino 
acids present in the EDN3 peptide, suggesting conjugation of endothelin-3 peptides to CPNPs. 
Given the complexity of the amino acid mixture in EDN3 (21 amino acids), it is difficult to indicate 
to which transitions correspond to particular functional groups of EDN3. To the best of our 
knowledge, the characteristic vibration band of the NH3
+ group of amino acids and the O-H bond 
in the acid group appear in the 3000-3500cm−1 range.167-169 The COO− asymmetric and symmetric 
stretching vibrations of carboxylic acid are observed at 1615 and 1410 cm−1, respectively.167-169 
The band at 1337-1350 cm-1 is attributed to the CH2 twisting mode.
168 The peak at 2100 cm−1 is 
attributed to the combination band, which is the result of two fundamental frequencies being 
excited simultaneously so that the excitation is allowed by symmetry.168, 169 The peak at 1750 cm-
1 is attributed to carbonyl groups present in amides.170 167 
 
 
 
 
 
 
 
 67 
 
Figure 34: FTIR spectra acquired for the raw materials PCPDTBT used in nanoparticle fabrication. 
 
Figure 35: FTIR spectra acquired for the raw materials PS-PEO-COOH used in nanoparticle 
fabrication. 
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Figure 36: FTIR spectra acquired for the obtained conjugated polymer nanoparticles CPNPs. 
 
 
Figure 37: FTIR spectra acquired for the obtained conjugated polymer nanoparticles EDN3-
CPNPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000 3500 3000 2500 2000 1500 1000
65
70
75
80
85
90
95
100
105
T
ra
n
s
m
it
ta
n
c
e
 (
%
)
Wavelength(cm-1)
 CPNPs
C-H   
 O–H 
COO
 - 
 
C–O 
 
 
4000 3500 3000 2500 2000 1500 1000
86
88
90
92
94
96
T
ra
n
s
m
it
ta
n
c
e
 (
%
)
Wavelength(cm-1)
EDN3-CPNPs
O–H 
C-H   
 
CO2 
C–O 
 
COO
 - 
 
 69 
Ligand attachment to CPNPs was further confirmed and quantified by the Extra Sense BCA 
Protein Assay.171 BSA is used as a standard for the BCA protein assay at the working range from 
0 to 40 μg/mL (150 μL per well in triplicate). The sensitivity of the assay was improved by 
allowing the color to develop for 1−12 h at 37 °C, rather than the recommended period of up to 2 
h. We avoided excessive incubation to prevent the absorbance from exceeding 1 to ensure we 
remain within the linear range of Beer’s Law. The absorbance was measured at the maximum 
absorbance (570 nm). We prepared a standard curve by plotting the average blank-corrected 570 
nm reading for each BSA standard vs. its concentration in μg/mL (Figure 39). The protein 
concentration of the EDN3-CPNPs sample fell within the linear working range; hence, the protein 
concentration of samples was determined in the BCA protein assay by comparison with the 
standard curve. 
Qualitatively, (Figure 38A) wells on the top right show the expected purple color due to 
the formation of EDN3/Cu2+ complex (as an intermediate that reacts with BCA), confirming our 
synthesized nanoparticles (14 µg/mL EDN3-CPNPs) contain EDN3 polypeptides. However, wells 
on the top right containing unmodified CPNPs (without EDN3 groups on CPNPs surface but              
-COOH groups present) 14 µg/mL also show the purple color but displayed lower color intensity 
than the EDN3-CPNPs (Figure 38B). Thus, we next sought to evaluate the reason for the color 
formation of the unmodified CPNPs with the assay reagent. First, the BCA working reagent was 
applied to aqueous suspensions of uncoated PCPDTBT NPs (without any -COOH or EDN3 groups 
present on NPs surface) in the bottom right wells. The result did not show the purple color indicated 
above, while the wells are still green (color of PCPDTBT nanoparticles), which suggests that -
COOH groups on the surface of the coated CPNPs are probably involved in the color development. 
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Second, the BCA working reagent was applied to a small amount of the raw materials of 
PCPDTBT and PS-PEO-COOH powders. The result show PCPDTBT polymer is not soluble in 
the aqueous BCA working reagent. However, PS-PEO-COOH showed purple color with the BCA 
working reagent immediately, further indicating that the -COOH group located on the surface of 
the non-functionalized CPNPs is involved in the color development with the BCA assay (Figure 
40). 
Quantitatively, due to these findings, we expect not all carboxylic groups on CPNPs are 
modified by endothelin 3. We, therefore, modified the quantitative analysis to determine the total 
amount of EDN3 attached to the CPNPs by subtracting the absorbance (A) obtained from CPNPs 
from the absorbance obtained from EDN3-CPNPs:  
(𝐴) EDN3 − CPNPs − (A) CPNPs = (A) Sample  ( 2 ) 
The standard BSA absorbance curve of at a wavelength of 570 nm was used to determine 
the concentration of the endothelin peptide attached to the CPNPs through: 
(A) Sample−(A) Sample Blank
(A) Standard
 × Standard Conc. ( 3 )  
From our data and equation 3, the surface conjugated EDN3 concentration for the 14 
µg/mL EDN3-CPNPs sample was determined to be 7.65 µg/mL. We also determined the percent 
yield of EDN3 conjugation to the CPNPs surface by: 
Percent yield =  
Actual yield
Theoretical yield 
 × 100%    ( 4 )  
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Knowing that we initially applied 10.00 µg/mL, the percent yield of EDN3 conjugation to the 
CPNPs surface is 76.5 ± 1.41%. 
 
Figure 38: (A) Schematic illustration of the treatment procedure for building a standardization 
curve for BCA assay of three different replicate experiments (B) A principal of the bicinchoninic 
acid (BCA) assay. 
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Figure 39: Absorbance plot obtained for bovine serum albumin (BSA) by using microplate 
procedure. 
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Figure 40: The proposed mechanism of the bicinchoninic acid (BCA) assay principle. 
4.4 Determination of Particle Size, Polydispersity Index (PDI), and ζ-Potential (ZP)  
We characterized the size and surface charge of the CPNPs by dynamic light scattering 
(DLS), transmission electron microscopy (TEM), scanning transmission electron microscopy 
(STEM), and ζ potential measurements. The average diameter and ζ potential of EDN3-CPNPs 
measured with DLS were around 62 nm and −54.5 mV, respectively (Figure 42A, C) and (Table1). 
The EDN3-CPNPs size is monodisperse and ideal for cellular internalization.172 The average 
 74 
diameter and ζ potential of CPNPs we prepared without further functionalization were about 58 
nm and −34.2 mV (Figure 42C) and (Table1). A slight increase in the hydrodynamic diameter 
from 58 to 62 nm from CPNPs to EDN3-CPNPs may be attributed to the −COOH and −COEDN3 
surface coatings. Our findings for CPNPs of PCPDTBT without further surface coating and further 
modifications are in line with previous findings. Our nanoparticles exhibited a negatively charged 
surface (−26.2 mV) with a hydrodynamic diameter of approximately 18.2 nm (Table 1), which is 
significantly smaller than the previously reported value of 75 nm with a negatively charged surface 
(−30 mV) that was prepared in a similar manner.173 The difference in particle size is likely due to 
the difference in the ratio of injected volume versus water volume and control of injection speed, 
which are factors that strongly affect particle size (besides initial polymer concentration).                   
In addition, more vigorous stirring or sonication during injection also allows for smaller particle 
sizes. The average size of the EDN3-CPNPs as measured by TEM and STEM exhibits an average 
diameter at around 62 nm (Figure 43A-D) and (Table 1). More importantly, the EDN3-CPNPs 
exhibit a comparable average diameter of approximately 62 nm on DLS, TEM, and STEM. The 
images obtained by TEM and STEM indicate some aggregation, while DLS demonstrated 
monodisperse particles. This was likely caused by the fact that TEM measured the diameter of the 
EDN3-CPNPs after they had been dried on the surface of the TEM grid, whereas DLS measured 
the diameter in aqueous solution.174-176 Transmission electron microscope (TEM) results 
confirmed the formation of the nanoparticles with the size around 62 nm. The zoomed-in TEM 
images suggest a polycrystalline structure. 
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Table 1: Characteristics of PCPDTBT NPs, CPNPs, and EDN3-CPNPs. 
 
Importantly, EDN3-CPNPs demonstrated a substantial increase in negative surface charges 
compared to the non-functionalized CPNPs. This finding further confirms the presence of 
endothelin molecules on the nanoparticle surface since the −COOH group of EDN3 will add a 
negative surface charge. The high negative surface charge contributed to the stability of the 
suspension and prevented them from aggregation in aqueous solution, typically a value in excess 
of −30 mV indicates good stability (Figure 41).177-181 The value of the ζ potentials we measured 
suggest stability of the colloidal CPNPs and EDN3- CPNPs (CPNPs, −34.2 mV = moderate 
stability; EDN3- CPNPs, −54.5 mV = good stability), respectively.  
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Figure 41: Stability of suspensions with relation to zeta potential. 
Indeed, EDN3-CPNPs and CPNPs showed high stability in DI water, for up to 6 months at 
4 °C with the absence of aggregation and with consistent ζ potential (Figure 42B, D, E). TEM 
elemental analysis of EDN3-CPNPs (Figure 42F) confirmed that the nanoparticles contain iron (as 
Fe3+), presumably as ferric chloride since the preparation of this polymer involves iron (III) 
chloride as a catalyst,137, 139, 142, 143.  
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Figure 42: (A) Distribution of hydrodynamic diameters of the EDN3-CPNPs in DI water measured 
by DLS. (B) Diameters of EDN3-CPNPs stored at 4 ⁰C as a function of time, up to 6 months. (C) 
Zeta potential measurements of the CPNPs and EDN3-CPNPs in DI water (-34.7 mV and -54.6 
mV nm). The zeta potential supports the well-dispersed nature of the nanoparticles. Time-
dependent zeta potential measurements of the (D) CPNPs and (E) EDN3-CPNPs in DI water as 
stored at 4 ⁰C, for up to 6 months. (F) TEM elemental analysis was utilized to verify the presence 
of iron of the obtained EDN3-CPNPs. 
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Figure 43: (A) TEM images of EDN3-CPNPs (scale bar is 50 nm) exhibit polycrystalline structure 
and uncoated PCPDTBT nanoparticles (scale bar is 20 nm). (B) STEM image of EDN3-CPNPs, 
scale bar is 100 nm. (C) Observation of cellular uptake and localization of EDN3-CPNPs for A375 
melanoma cell line (1.4 µg/mL internalized and damaged the nucleus), scale bar is 100 nm. (D) 
Localization of EDN3-CPNPs for Malem-3M melanoma cell line (1.4 µg/mL internalized and 
damaged the nucleus), scale bar is 100 nm. (E) Zoomed-in TEM image shows the nanoparticles 
localized inside the nuclei of A375 cells (scale bar is 100 nm). (F) Zoomed-in TEM image shows 
the nanoparticles localized inside the cytoplasm of Malme-3M cell only (scale bar is 100 nm). In 
this case the EDN3-CPNPs did not cause damage to the nucleus.   
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4.5 EDN3-CPNP as Anti-Tumor Cell Effect 
Next, we assessed the CDT effectiveness of CPNPs and EDN3-CPNPs on a normal cell 
line and five different types of cancer cell lines. We studied three different types of melanoma skin 
cancer cell lines (A375, Malme-3M, and SK-Mel-28), two different nonmelanoma cell lines (Hepa 
1−6 and T24), and one healthy cell line (AML12). These were treated with different doses (14, 
1.4, 0.14, and 0.014 µg/mL) of CPNPs and EDN3-CPNPs, and cell viability was tested by MTS 
assay. The results are shown in 44A-F. We observed that cell killing was higher with targeted 
EDN3-CPNPs for A375 and Malme-3M compared to the untargeted CPNPs. These melanoma 
cells are strongly positive for endothelin receptor B.182 Moreover, for these cell lines, we observed 
a significant increase in cell death relative to other cell lines (SK-Mel-28, T24, Hepa 1−6, and 
AML12). These results suggest effective targeting of EDN3-CPNPs to tumor cells strongly 
overexpressing EDNRB with dose-dependent tumor cell killing.107, 183 The data in Figure 44A, B 
suggest that the CDT performance in terms of absolute tumor cell killing with targeted EDN3-
CPNPs is slightly better for A375 compared to Malme-3M, probably because A375 exhibits               
a somewhat higher expression of the endothelin receptor B on its cell surface compared to Malme-
3M.24, 182, 184 The specificity of the EDN3-CPNPs appears to be better for Malme-3M, however, as 
suggested by the larger difference in cell viability between treatment with targeted and untargeted 
CPNPs.  
The human bladder cancer cell (T24) is moderately positive for endothelin receptor B 
compared to A375 and Malme-3M.185, 186 We observed that for T24, the cellular viability at 14 
µg/mL of EDN3-CPNPs demonstrated a decrease in viability to 45% after 24 h. Unlike for A375 
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and Malme-3M, there is no significant difference between targeted and untargeted CPNPs at lower 
doses. The CDT efficiency is much lower for T24 than for A375 and Malme-3M though. The first 
result is well explained by the lower EDNRB expression levels of T24. We can only speculate at 
this time that the lack of differentiation between targeted and untargeted CPNPs in terms of CDT 
effectiveness is due to the properties of T24, possible metabolic rate, or nonspecific internalization 
pathways. Nonspecific CPNPs uptake across the studied cell lines is also suggested to be possible 
due to attractive interaction of the anionic CPNPs (ζ potential −34.7 mV) with the relatively 
positively charged EDNRB.187, 188 SK-Mel-28 has limited overexpression of EDNRB compared to 
the tumor cells discussed above.182, 189 Little difference with the normal control (AML12) and non-
EDNRB overexpressing tumor cells was observed for SK-Mel-28 except for the highest applied 
dose, where a modest CDT response is evident. Hepa 1−6 and AML12 showed no significant 
difference between EDN3-CPNPs and CPNPs with limited loss of cell viability, reflecting their 
lack of endothelin receptors.13 We observed that viability decreased similarly to 80% for both cell 
lines after 24 h for the highest applied dose. Production of minimal amounts of hydrogen peroxide 
by healthy human cells of AML12 relative to tumor cells in our study is another possible reason 
for the absence of CDT effectiveness in addition to the lack of EDNRB on the cell surface.62  
Morphology changes in TEM images further indicate that CDT occurred in EDN3-CPNPs 
treated cells, resulting in cell damage. The TEM and STEM images in Figure 43C-F show 
nanoparticles are localized around and inside the nucleus for A375, and in the cytoplasm for 
Malme-3M.190-193 The nanoparticle size determined from these data is approximately 62 nm in 
agreement with DLS, TEM, and STEM data (Figure 43A, B) and (Table 1). From TEM, we can 
further observe that, for example, the 1.4 µg/mL dose of EDN3-CPNPs internalized and damaged 
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the nucleus of A375 cells (Figure 43C). A TEM control experiment (Figure 45 A, B) on untreated 
cells shows that such damage does not occur in the absence of EDN3-CPNPs, indicating that the 
observed effects are due to CDT. The pristine nuclei appear with dark contrast in the TEM images 
shown in Figure 45 A, B as expected. We also investigated the EDN3 targeting effect for the 
nanoparticles to the melanoma cell lines. TEM images in Figure 45 C, D indicate that fewer 
nanoparticles are present compared to the melanoma-targeted EDN3-CPNPs, although damage to 
the nucleus is still apparent. These observations are consistent with the data presented in Figure 
44.  
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Figure 44: In vitro cell cytotoxicity as measured by MTS assay upon different doses of CPNPs 
(gray column) and EDN3-CPNPs (black column) in the cell culture medium for a period of 
incubation of 24 h at 37 °C of (A) A375, (B) Malme-3M, (C) SK-Mel-28; (A−C), (D) Hepa 1−6, 
(E) T24; (D, E) as nonmelanoma cell lines, and (F) AML12 as a healthy cell line. Error bars 
represent the quality deviation of the mean ± s.d. (n ≥ 3). A P-value < 0.05 was considered 
statistically significant and nonsignificant for P > 0.05. *P < 0.05, and **P < 0.01. 
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Figure 45: TEM control experiment on untreated cells. (A) A375 and (B) Malme-3M.TEM 
experiment on treated cells with CPNPs. (C) Malme-3M and (D) A375 cells. (E) and (F) The 
optical microscope images of A375 cell line incubated with 14 µg/mL EDN3-CPNPs a period of 
incubation of 24 h in the dark in 75 cm2 cell culture flask. 
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4.6 Ferroptosis as The Tumor Cell Killing Mechanism 
To confirm the role of iron in the EDN3-CPNPs-mediated CDT, it is crucial to quantify 
the iron content in the sample. A ferrozine based assay was used in determining the iron 
concentration of EDN3-CPNPs based on the absorbance of the ferrozine−Fe2+ complex, the 
intensity of which can be measured spectrophotometrically at 570 nm. One of the main advantages 
of the ferrozine assay is that several samples can be measured at once. To estimate the iron 
concentration of the EDN3-CPNPs suspension, a standard curve of absorbance at 570 nm as a 
function of Fe3+ concentration was created using 8 known iron standard samples at the linear 
working range from 0 to 40 μg/mL (Figure 47). FeCl3 standard samples were dissolved in 0.01 N 
HCl, followed by the addition of the ferrozine-detection reagent (6.5 mM ferrozine, 6.5 mM 
neocuproine and 1 M ascorbic acid dissolved in acetate buffer at pH 4.5) to form complexes. On 
the other hand, EDN3-CPNPs suspension of 14 µg/mL was dissolved in 1.4 N hydrochloric acid 
and kept for 2 h at 60 °C in a water bath sonicator to allow the mineralization and the complete 
dissolution of the EDN3-CPNPs carrying iron, followed by the addition of an equal volume of the 
ferrozine detection reagent to form complexes. In contrast, the blank consists of HCl 0.01 N and 
an iron-detection reagent with no iron. The Fe2+−ferrozine complex was performed on 96-well 
plates, and the absorbance was measured at 570 nm on a microplate reader (200 μL per well in 
triplicate). The net absorbance at 570 nm is found by subtracting the absorbance (A570) of the blank 
from the recorded A570 values for the FeCl3 standard samples and EDN3-CPNPs sample. The iron 
content of the EDN3-CPNPs sample was then determined by comparing its absorbance to that of 
a range of standard concentrations of equal volume that had been prepared similar to the EDN3- 
 85 
CPNPs solution. The iron concentration was calculated to be 5.2 µg/mL = 0.033mM for 14 µg/mL 
EDN3-CPNPs suspension.  
It is noteworthy that the presence of iron (III) is an interfering agent in the analysis of the 
ferrozine assay. Therefore, ascorbic acid is added as a reducing agent to ensure an entire reduction 
of the iron is in the divalent. Ascorbic acid reduces the ferric to ferrous ions, which react with the 
chelator ferrozine to form a deeply colored purple complex with an absorption maximum near 562 
nm, allowing for quantification. Next, for the experiments of the microplate, we applied the iron-
detection reagent without ascorbic acid to 14 µg/mL EDN3-CPNPs to determine if the formation 
of the purple complex is possible. The result did not show the typical color, but instead, it gave us 
a nutty color, confirming this assay works only in the presence of ferrous ions. Thus, the assay 
depends on the presence of ascorbic acid (Figure 46A, B). This result corroborates that our EDN3-
CPNPs contain ferric ions as ferric chloride because the preparation of this polymer involves iron 
(III) chloride as a catalyst,137, 139, 142, 143. 
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Figure 46: (A) Schematic illustration of the treatment procedure for building a standard curve for 
the ferrozine assay of three different replicate experiments. The inset picture shows a yellow 
colored iron-chelating reagent which was stored in the dark at room temperature. (B) Chemical 
tool for the colorimetric detection of iron ions and the complex formed with ferrozine. 
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Figure 47: Calibration curve obtained for FeCl3. 
By contrast, the ferrozine assay in the presence of the ascorbic acid takes on a 
purple/fuchsia color tone, indicating Fe3+ is present. Besides iron, copper is the only metal that 
could react with ferrozine to form a colored complex.194 Therefore, neocuproine is also present in 
the color reagent to prevent copper interference. To investigate whether the ferrozine-based 
quantitation of iron can be perturbed by a copper divalent cation, an experiment was conducted to 
determine the intensity of the purple complex formed by applying the iron-detection reagent 
without neocuproine to 14 µg/mL EDN3-CPNPs. The result did not show any noticeable changes 
in color intensity and did not alter the absorbance of the Fe2+−ferrozine complex at 570 nm, 
indicating that copper ions do not exist to interfere with iron quantification. A stable Fe2+−ferrozine 
complex that forms in aqueous solution between the pH values of 4 and 9 was previously 
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reported194, as such careful sample preparation is crucial. Our results demonstrated the EDN3- 
CPNPs contains the iron needed to kill cancer cells via the ferroptosis mechanism. Finally, the 
resulting CPNPs showed another area of study. It showed reasonable sensitivity towards copper 
ions. It might represent a promising sensor for copper ions in alkaline environments. This lead to 
the hypothesis that, in the present copper ions, not only lead to the specific cross-linked formation 
of the purple complex that integrate copper ions with the protein on the surface of the CPNPs but 
also lead to the creation of the purple complex with the carboxyl terminated units on the surface 
of the non-functionalized CPNPs. This task was accomplished by blending CPNPs with 
BioVision’s Extra Sense™ BCA Protein Assay Kit. 
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CHAPTER FIVE: CONCLUSIONS 
In summary of this dissertation research program, the resulting CPNPs obtained from PTB7 
conjugated polymer-functionalized polypeptide endothelin-3 (human, rat) fabricated by a 
reprecipitation method was investigated. The results demonstrated that there was no significant 
tumor targeting and treating via photodynamic therapy in vitro. On the other hand, a novel 
conjugated polymer CPNP that enables tumor-targeted chemodynamic therapy (CDT) is reported. 
The CPNP delivers iron to the targeted tumor cells to enable ferroptosis through Fenton chemistry 
that produces reactive oxygen species (ROS). No activation by external stimuli is needed for ROS 
production. Our CDT platform was tested using melanoma as the case study. The melanoma-
targeted EDN3-CPNPs demonstrated significant CDT with respect to A375 and Malme-3M 
melanoma. Herein we showed that the melanoma endothelin axis was successfully targeted 
through the overexpressed EDNRB receptor on the surface of these cancer cells. In comparison, 
no apparent CDT effect was observed for the healthy cell line AML12 and the non-EDNRB 
receptor overexpressing tumor Hepa 1−6 except at higher doses. We expect that, due to the flexible 
design of the CPNP, other tumors can be targeted by exchanging the targeting ligand. Our studies 
reported herein thus lay the groundwork for a promising new class of nanomedicines. Therefore, 
it will be useful to explore combined chemodynamic and photodynamic therapy for treating 
melanoma. Moreover, it is critical to determine whether this finding could have consequences on 
tumor growth in vivo.  
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APPENDIX A: COPYRIGHT PERMISSION 
 
Figure 48: TEM image of blank grid. 
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Figure 49: TEM elemental analysis was utilized to verify the presence of iron of the obtained 
EDN3-CPNPs. 
 
 
Figure 50: TEM elemental analysis was utilized to verify the presence of iron of the raw material 
of PCPDTBT. 
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Figure 51: TEM elemental analysis was utilized to verify the presence of iron of the obtained 
CPNPs. 
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